Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 30 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Razis, Evangelia [Clear All Filters]
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). The Role of CXCL13 and CXCL9 in Early Breast Cancer..
Clin Breast Cancer. 20(1), e36-e53.
(2020). Is There an Independent Role of TERT and NF1 in High Grade Gliomas?.
Transl Oncol. 13(2), 346-354.
(2020). Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab..
ESMO Open. 4(2), e000441.
(2019). Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab..
Transl Oncol. 12(5), 739-748.
(2019). Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome..
Clin Breast Cancer. 19(2), 113-125.e4.
(2019). Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials..
Clin Breast Cancer. 18(1), 53-62.e3.
(2018). Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab..
Cancer Genomics Proteomics. 15(6), 461-471.
(2018). Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study..
PLoS One. 13(12), e0207707.
(2018). Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data..
J Clin Oncol. 36(10), 981-990.
(2018). Central nervous system tumours among adolescents and young adults (15-39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US..
Eur J Cancer. 86, 46-58.
(2017). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017). Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers..
Cancer Genomics Proteomics. 14(3), 181-195.
(2017). Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer..
Anticancer Res. 37(5), 2323-2334.
(2017). Disease evolution and heterogeneity in bilateral breast cancer..
Am J Cancer Res. 6(11), 2611-2630.
(2016).
(2016).
(2016). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015). PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients..
Cancer Chemother Pharmacol. 75(6), 1289-301.
(2015). EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab..
J Cancer Res Clin Oncol. 140(5), 737-48.
(2014).
(2014). Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes..
BMC Cancer. 13, 49.
(2013). Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial..
PLoS One. 8(7), e69256.
(2013). The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab..
Clin Colorectal Cancer. 12(4), 267-274.e2.
(2013). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012).